Di Zhe Pharmaceuticals (stock code: 688192.SH) announced its 2026 interim report on August 20, 2026, revealing a revenue of $523...
-
-
Recent Updates
- Di Zhe Pharmaceuticals Reports Revenue Surpassing $500 Million in First Half, Advances Globalization Strategy into Innovation Value Realization Phase
- Clps Successfully Modernizes 30-Year-Old Mortgage System of International Bank with AI
- Sipei Health Technology Turns Profitable, Enters New Phase of High-Quality Development in 2026
- China’s semiconductor equipment imports rise 9% YoY in July as logic chip spending accelerates
- CBB 2026: Global Liquid Food Industry Chain Event to Open in Shanghai This October
- China’s Industrial Robots Transitioning to Key Roles Across Sectors
- China-Related Dispute: CK Hutchison Seeks $1.9 Billion over Panama Assets Loss
- Unitree Robotics Soars on IPO Debut, Signals China’s Hard-Tech Strength
- Bilibili Challenges Crunchyroll with Competitive Pricing and Diverse Content Library
- Shanghai Electric Catalyst in Pioneering Biomethanol Venture
Blogroll